The global spatial genomics and transcriptomics market is projected to grow from USD 0.60 billion in 2025 to USD 1.90 billion by 2035 at a 12.23% CAGR. Growth is driven by increased adoption of AI-powered spatial biology technologies, precision medicine initiatives, and high-resolution molecular profiling in oncology and translational research. North America is expected to lead with 46% market share, while Asia Pacific shows the highest growth rate at 16.69% CAGR.

The omics-based clinical trials market is experiencing robust growth, expanding from $31.71 billion in 2025 to $34.49 billion in 2026 with an 8.8% CAGR, and projected to reach $47.78 billion by 2030. Growth is driven by increasing demand for personalized medicine, genomics advancements, AI-enabled patient recruitment, and biomarker-driven trial designs. North America leads the market while Asia-Pacific shows rapid expansion potential.

Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta slid 4% on soft guidance, while Moderna rallied 14% on bullish forecasts. Intel and AMD gained on analyst upgrades. Energy stocks outperformed as crude rose 2.7% to $61/barrel.

Lane Generational, a Massachusetts-based investment advisor, completely sold its $3.6 million stake in Bruker during Q3 2025, exiting all 87,607 shares amid the company's challenging market performance.

The global molecular spectroscopy market is projected to grow from USD 6.97 billion in 2024 to USD 9.04 billion by 2034, driven by expanding healthcare applications, research growth, and technological advancements in drug discovery and diagnostics.

The next-generation proteomics market is projected to expand rapidly between 2025-2034, driven by technological advancements, rising chronic disease prevalence, and increasing demand for personalized medicine across pharmaceutical, biotechnology, and diagnostic sectors.

The global PFAS testing market is projected to grow from $306.60 million in 2024 to $1.25 billion by 2037, driven by increasing environmental and health regulations around 'forever chemicals' across North America, Europe, and Asia.

Biognosys has expanded its contract research services to include quantitative metabolomics and lipidomics, leveraging biocrates MxP® Quant 1000 kit and Bruker's mass spectrometry platforms to provide comprehensive multiomics research capabilities.

Medical device company Bruker announced a $600 million mandatory convertible preferred stock offering to retire debt, causing an 11.68% stock price decline on Wednesday.

The Atomic Spectroscopy Market is projected to grow from USD 1.57 Billion in 2024 to USD 2.37 Billion by 2032, with a CAGR of 5.28%, driven by increasing demand for precise elemental analysis in pharmaceuticals, environmental monitoring, and food safety.

Bruker reported Q2 2025 earnings with GAAP revenue of $797.4 million, missing analyst estimates and declining 0.4% year-over-year. The company experienced softer demand in U.S. academic and biopharma markets, leading to margin compression and reduced full-year guidance.

Wall Street indices extended record highs on strong earnings and investor confidence, with gold prices surging to $3,400 amid dollar weakness and speculation about Federal Reserve leadership.